May 19, 2025 - Business

23andMe assets being sold to Regeneron Pharma for $256M

Dan Primack

Illustration of a price tag on a DNA strand. — Illustration: Lindsey Bailey/Axios

Regeneron Pharmaceuticals has agreed to acquire the assets of bankrupt genetic testing company 23andMe for $256 million.

Why it matters: 23andMe holds personal genetic data on more than 15 million customers, and there have been widespread concerns about what a buyer could do with that information.

In a press release, Regeneron pledged to "ensure compliance with 23andMe's consumer privacy policies and applicable laws with respect to the treatment of customer data."

By the numbers: 23andMe went public via SPAC in 2021 at a $3.5 billion valuation, and briefly was valued at around $6 billion.

It previously had raised over $800 million in VC funding.

The bottom line: This is a big loss for 23andMe co-founder and former CEO Anne Wojcicki, who'd been trying to buy the company since last summer.

Add Axios on Google

23andMe assets being sold to Regeneron Pharma for $256M

What to read next